This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Lumason
- Generic Name
- 1,2-Distearoyllecithin
- DrugBank Accession Number
- DB14099
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for 1,2-Distearoyllecithin (DB14099)
- Weight
- Average: 790.161
Monoisotopic: 789.624755796 - Chemical Formula
- C44H88NO8P
- Synonyms
- 1,2-Distearoyl-sn-glycero-3-phosphocholine
- 1,2-Distearoylphosphatidylcholine
- Dioctadecanoyl phosphatidylcholine
- Dioctadecanoyllecithin
- Distearoyl-DL-phosphatidylcholine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image LumaSon 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Kit Intravenous; Intravesical Bracco Suisse SA 2015-01-15 Not applicable US 
LumaSon 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Injection, powder, lyophilized, for suspension Intravenous; Intravesical Bracco Diagnostics Inc 2021-04-01 Not applicable US LumaSon 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg) Kit Intravenous; Intravesical Bracco Diagnostics Inc 2015-01-15 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phosphatidylcholines. These are glycerophosphocholines in which the two free -OH are attached to one fatty acid each through an ester linkage.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Glycerophospholipids
- Sub Class
- Glycerophosphocholines
- Direct Parent
- Phosphatidylcholines
- Alternative Parents
- Phosphocholines / Fatty acid esters / Dialkyl phosphates / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives show 2 more
- Substituents
- Aliphatic acyclic compound / Alkyl phosphate / Amine / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diacylglycero-3-phosphocholine / Dialkyl phosphate / Dicarboxylic acid or derivatives / Fatty acid ester show 14 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- a phosphatidylcholine (L-1-LECITHIN)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EAG959U971
- CAS number
- 4539-70-2
- InChI Key
- NRJAVPSFFCBXDT-UHFFFAOYSA-N
- InChI
- InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3
- IUPAC Name
- (2-{[2,3-bis(octadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
- SMILES
- CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC
References
- General References
- Not Available
- External Links
- ChemSpider
- 58655
- 1426933
- ChEMBL
- CHEMBL113644
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Diagnostic Abdominal Injuries / Falls, Accidental / Motor Vehicle Injury / Physical Abuse 1 4 Recruiting Diagnostic Abdominal Trauma 1 4 Recruiting Diagnostic Hepatic Disease 1 4 Recruiting Diagnostic Renal Malignant Tumor 1 4 Recruiting Diagnostic Trauma Abdomen 1 4 Terminated Diagnostic Crohn's Disease (CD) 1 4 Terminated Diagnostic Liver Biopsy 1 4 Withdrawn Diagnostic Bone Marrow Transplant Complications / Sinusoidal Obstruction Syndrome (SOS) / Stem Cell Transplant Complications / Veno Occlusive Disease, Hepatic 1 4 Withdrawn Diagnostic Neonatal Post-Hemorrhagic Hydrocephalus 1 3 Completed Diagnostic Coronary Artery Disease (CAD) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension Intravenous; Intravesical Kit Intravenous; Intravesical - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5686060 No 1997-11-11 2017-11-11 US US10232061 No 2019-03-19 2038-07-06 US US10335502 No 2019-07-02 2038-07-06 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.16e-05 mg/mL ALOGPS logP 5.92 ALOGPS logP 9.89 ChemAxon logS -7.6 ALOGPS pKa (Strongest Acidic) 1.86 ChemAxon pKa (Strongest Basic) -6.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 111.19 Å2 ChemAxon Rotatable Bond Count 44 ChemAxon Refractivity 234.27 m3·mol-1 ChemAxon Polarizability 98.65 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 18, 2018 18:57 / Updated at June 12, 2020 16:53